XyloCor Therapeutics Commences Phase 2 Component of Phase 1/2 EXACT Clinical Study of XC001 Gene Therapy for Refractory Angina

July 27th, 2021|Cell and Gene Therapy, Innovation, Regional News Roundup|Comments Off

$XyloCor Therapeutics Commences Phase 2 Component of Phase 1/2 EXACT Clinical Study of XC001 Gene Therapy for Refractory Angina$

A clinical-stage biopharmaceutical company has announced the completion of a new development.

Article from Business Wire